In-Depth Examination Of 4 Analyst Recommendations For ANI Pharmaceuticals
Portfolio Pulse from Benzinga Insights
ANI Pharmaceuticals (NASDAQ:ANIP) has been analyzed by four analysts, showing a range of perspectives from bullish to bearish. The average 12-month price target is $85.5, with a high of $94.00 and a low of $60.00. Analysts have decreased the average price target by 3.66%. The company has shown a revenue growth rate of 18.44% and maintains a strong financial position with a low debt-to-equity ratio.
September 17, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
ANI Pharmaceuticals has received mixed analyst ratings, with a recent decrease in the average price target by 3.66%. The company shows strong financial health with a revenue growth rate of 18.44% and a low debt-to-equity ratio.
The mixed analyst ratings and decrease in average price target suggest a neutral short-term impact on ANIP's stock price. However, the company's strong financial health, indicated by its revenue growth and low debt-to-equity ratio, provides a positive outlook, balancing the negative sentiment from the price target decrease.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100